Claritev Corporation (NYSE: CTEV) announced on October 15, 2026, that it has appointed Jennifer (Jenni) Main to its Board of Directors, effective immediately. The appointment fills a newly created directorship, increasing the size of the Board from eleven to twelve members. The Board’s Nominating and Corporate Governance Committee recommended the appointment.
Main will serve as a Class II director and will be a member of the Audit Committee. Concurrently with her appointment, Mr. Jason Kap has ceased serving as a member of the Audit Committee. The Company stated that Main does not have a family relationship with any directors or executive officers and does not have a direct or indirect material interest in any required transactions.
Main brings more than three decades of leadership experience across healthcare, technology, government, and finance. Currently, she serves as Chief Financial Officer of RealMDai (dba Certuma) and Overture Life, roles she has held since March 2026. Previously, she served as Chief Financial Officer and Chief Operating Officer of Amalgam Rx from 2021 to 2026.
Main previously held several leadership roles at the Centers for Medicare & Medicaid Services (CMS), most recently serving as Chief Operating Officer from 2018 to 2021. In that role, she oversaw operational execution across the agency's Medicare, Medicaid, and federal health insurance marketplace program. She also served as Chief Financial Officer for the Troubled Assets Relief Program (TARP) at the U.S. Department of Treasury, where she led the development and implementation of financial management services for the $700 billion program established in response to the 2008 financial crisis.
Main holds a master’s degree in public policy from Harvard University and a bachelor’s degree in history from Cornell University. She will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation policy described in the proxy statement filed with the SEC on March 20, 2026.
